Travere therapeutics to present abstracts at american society of nephrology (asn) kidney week 2024

Data presentations highlight the results for filspari ® (sparsentan), the only approved kidney-targeted medicine for iga nephropathy, when used as a first-line treatment, and in combination with other therapies late-breaking presentation details outcomes of sparsentan's effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis san diego, oct. 14, 2024 (globe newswire) -- travere therapeutics, inc., (nasdaq: tvtx) today announced that the company will present 11 abstracts, including one late-breaking abstract at the upcoming american society of nephrology (asn) kidney week 2024 in san diego, ca, october 23-27, 2024. presentations will include new data from the spartan study highlighting efficacy and safety results of filspari (sparsentan) in iga nephropathy (igan) when used as a first-line treatment in newly diagnosed igan patients, an analysis from the protect study examining the clinical benefit of filspari in igan regardless of participants' baseline proteinuria, as well as patient-reported outcomes from the protect and duplex studies.
TVTX Ratings Summary
TVTX Quant Ranking